Biological
Escherichia coli clinical trials
- studies test it
- 16
- open now
- 1
- in phase 3
- 3
- first study started
- 2014
Keep track of what changes. Save the Escherichia coli studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 1
- Phase 3
- 3
- Phase 4
- 7
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 4
Xiamen Innovax Biotech Co., Ltd (6) · Beijing Health Guard Biotechnology, Inc (5) · University Hospital, Linkoeping (1) · Jiangsu Province Centers for Disease Control and Prevention (1) · Jun Zhang (1) · NIZO Food Research (1) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (1)
Studies
Open first, then newest update. How each study uses Escherichia coli is read from its arms, and is right about nine times in ten.
Testing it · 16
- Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)RecruitingPhase 1Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNCT06314880Written as Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose)
- Individual Differences in Acute Response to Experimental Inflammation: Microcirculatory Changes and Psychological PredictorsCompletedNot applicableUniversity Hospital, LinkoepingNCT06618716Written as endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)
- Safety and Immunogenicity Study of Thiomersal-free Hepatitis E Vaccine in People Ages 16 Years and AboveCompletedPhase 4Xiamen Innovax Biotech Co., LtdNCT06564116Written as Thiomersal-free Recombinant Hepatitis E Vaccine (Escherichia Coli)
- A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) VaccineActive, not recruitingPhase 3Beijing Health Guard Biotechnology, IncNCT06207175Written as Nonavalent HPV study vaccine
- A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV VaccineCompletedPhase 2Beijing Health Guard Biotechnology, IncNCT05694728Written as Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
- A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV VaccineCompletedPhase 1Beijing Health Guard Biotechnology, IncNCT05680454Written as Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
- A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV VaccineStatus unknownPhase 3Beijing Health Guard Biotechnology, IncNCT05668572Written as Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)
- A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in ChinaActive, not recruitingPhase 3Beijing Health Guard Biotechnology, IncNCT05662020Written as Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)
- Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy FemaleCompletedPhase 4Xiamen Innovax Biotech Co., LtdNCT05426148Written as Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®
- A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy AdultsCompletedPhase 1Jiangsu Province Centers for Disease Control and PreventionNCT03966040Written as Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7
- A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial)CompletedPhase 4Xiamen Innovax Biotech Co., LtdNCT03365921Written as Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
- A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )CompletedPhase 4Xiamen Innovax Biotech Co., LtdNCT02964910Written as Recombinant Hepatitis E Vaccine (Escherichia Coli)
- A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule)CompletedPhase 4Xiamen Innovax Biotech Co., LtdNCT03168412Written as Recombinant Hepatitis E Vaccine (Escherichia Coli)
- Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin®）CompletedPhase 4Jun ZhangNCT02189603Written as Recombinant (E. Coli) Hepatitis E Vaccine
- Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. ColiCompletedNot applicableNIZO Food ResearchNCT02541695Written as E. coli strain E1392-75-2A
- A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)CompletedPhase 4Xiamen Innovax Biotech Co., LtdNCT02417597Written as Recombinant Hepatitis E Vaccine (Escherichia Coli)
Given in every arm · 1 — Escherichia coli is usual care beside what is tested
Codes
What other systems call Escherichia coli · ClinicalTrials.gg INT014965
- UNII (FDA) 514B9K0L10ESCHERICHIA COLIConfirmed FDA, Wikidata
- RxNorm 350202One source FDA
- Wikidata Q25419Escherichia coliConfirmed FDA, Wikidata
- NCI Thesaurus C14206Escherichia coliOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 514B9K0L10 | ESCHERICHIA COLI | Confirmed FDA, Wikidata |
| RxNorm | 350202 | — | One source FDA |
| Wikidata | Q25419 | Escherichia coli | Confirmed FDA, Wikidata |
| NCI Thesaurus | C14206 | Escherichia coli | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.